Introduction
Lung cancer remains the most prevalent malignant tumor in the respiratory system with the highest morbidity and mortality. 1, 2 Non-small-cell lung cancer (NSCLC) serves as a subtype of lung cancer and accounts for ~80%-85% of all lung cancers. 3 Because the great majority of NSCLC patients are diagnosed in the middle or terminal stage, clinical drug treatments have become the focus of NSCLC. 4 Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK ) is a transforming gene and a driver mutation in NSCLC, which has been identified to be closely associated with cancerogenesis and serves as a causative factor in patients with NSCLC. 5, 6 The resulting EML4-ALK fusion protein preserves the complete intracellular portion of ALK, and therefore, NSCLC cells with this fusion protein are highly sensitive to ALK tyrosine kinase inhibition, which could restrain tumor proliferation and induce tumor apoptosis. 7 Crizotinib, a specific ALK inhibitor, is beneficial for most patients with ALK-positive NSCLC but has no obvious therapeutic effect on a minority of patients due to the acquired resistance to cerizotinib. 8, 9 It has been reported that the mutations in the ALK domain or the activated bypass signaling pathways contribute to crizotinib resistance in NSCLC. [10] [11] [12] Cancer stem cells (CSCs), the aggressive subpopulation of cells within tumors, are responsible for tumorigenesis, relapse, and cancer metastasis associated with their capabilities of self-renewal and differentiation according to the CSC hypotheses. [13] [14] [15] Numerous studies have documented the existence of CSCs in various types of human cancers including NSCLC. 16, 17 Additionally, emerging evidence has validated the clinical relevance of CSCs, including an initial positive response to therapy and resistance to currently used chemotherapy and radiotherapy. 18 Chemotherapeutic agents are widely accepted as the standard therapy for patients with advanced NSCLC. Their effects are accompanied by chemotherapy resistance and multidrug resistance, which are possibly induced by the enrichment of CSCs. 16 Genetic and epigenetic mechanisms are implicated in the malignant reprogramming process correlated with the acquisition and maintenance of self-renewal and stemness features of CSCs. 19 It has been verified that ncRNAs, including miRNAs and lncRNAs, are involved in one such regulatory mechanism. For example, lncRNA HOTAIR and lncRNA MALAT1 play an important role in cancer metastasis. 20, 21 Of particular note is that long intergenic noncoding RNA, regulator of reprogramming (lincROR), located at chromosome 18q21.31, could reprogram differentiated cells to induced pluripotency stem cells and, therefore, is identified as a major regulator of pluripotency reprogramming. 22, 23 Moreover, Wang et al have shown the key role of lincROR in human embryonic stem cells as a potential self-renewal and pluripotency marker. 24 Accumulating studies have reported the involvement of lincROR in various cancers, including lung adenocarcinoma, 25 bladder cancer, 22 pancreatic cancer, 26 and breast cancer. 27 Specially, lincROR is reported to be involved in chemoresistance in docetaxel-resistant lung adenocarcinoma cells. 25 However, the potential roles of lincROR in the acquired resistance to crizotinib in NSCLC are not fully understood.
A previous study has demonstrated the association of stemness with EML4-ALK-driven tumorigenesis of NSCLC cells, verifying that the stem cell-like properties of NSCLC cells are increased both in vitro and in vivo by EML4-ALK. 28 Furthermore, lincROR plays an important role in the reprogramming process relative to stemness features of CSCs. However, little is known about the association between EML-ALK and lincROR concerning stem cell-like properties of NSCLC cells.
In this study, we first investigated the expression profile and prognosis of lincROR in tissues and its association with ALK using quantitative polymerase chain reaction (qPCR) assay. Subsequently, we examined the potential role of ALK and lincROR in stem cell-like properties of EML-ALK + cells. Additionally, the effects of crizotinib on lincROR expression were evaluated. Finally, we analyzed the role of lincROR in cells' chemoresistance to crizotinib according to cell viability assay. alK knockdown experiments siRNA for ALK (ALK-si) and negative control (NC) were obtained from RiboBio (Guangzhou, China). The sequence of ALK-si is listed in Table 2 . H3122 cell line was used for transfection with ALK-si. In brief, cells were planted into 12-well plates for 12 h and then transfected with ALK-si using X-treme GENE transfection reagent (Roche, Basle, Switzerland) according to the corresponding manufacturer's recommendations. After 24 h transfection, total RNA was isolated and then used for analysis.
Patients and methods

Patients' samples
lincrOr overexpression experiments pcDNA-lincROR was constructed by introducing a BamHI-EcoRI fragment containing the lincROR DNA into the same site in pcDNA3.1. H3122 and H2228 cells were transfected with pcDNA-lincROR using Lipofectamine 2000 (Thermo Fisher Scientific) under the manufacturer's protocol, respectively. RNA isolation was performed after 24 h transfection.
cell counting kit-8 (ccK-8) assay
A colorimetric assay was used to analyze the cell viability of H3122 and H2228 cells using the CCK-8 reagent (Beyotime Biotechnology, Shanghai, China), respectively. Cells transfected with pcDNA-lincROR or pcDNA control were set as the experimental or the control group. After 24 h transfection, the cells were planted into 96-well plates supplemented with 10 μL of CCK-8 reagent and then incubated for 1 h at 37°C. Subsequently, the transfected cells were separately treated with crizotinib (TargetMol, Shanghai, China) at various concentrations (0, 0.25, 0.5, 1.0, and 5.0 μM) and then cultured for 24 h. Finally, the cell viability was analyzed by measuring the OD at 450 nm wavelength using the Tecan M200 multimode microplate reader (Tecan, Mechelen, Belgium).
spheroid formation assay
Spheroid formation assay was performed to evaluate the capability of cell self-renewal using ultralow attachment surface 96-well culture plates. Cells transfected with ALK-si and pcDNA-lincROR, or ALK-si and pcDNA-control, or NC-si and pcDNA-control were, respectively, resuspended in 200 μL serum-free DMEM/F12 containing 20 ng/mL human Figure 1A , lincROR expression in EML-ALK + NSCLC tissues was significantly higher than that in EML-ALK − tumor tissues (P,0.01). The association between lincROR expression and prognosis was explored by Kaplan-Meier and log-rank tests. The median expression of lincROR in 68 EML-ALK NSCLC patients was defined as the cutoff to classify the patients into two groups (high expression and low expression). The progression-free survival of EML-ALK NSCLC patients was analyzed. A favorable prognosis was observed in low-lincROR expression patients with EML-ALK + NSCLC ( Figure 1B , P=0.027).
lincROR expression was decreased by alK knockdown
The ALK knockdown assay was conducted to further investigate the relationship between lincROR and EML-ALK. The expressions of ALK and lincROR were measured by qPCR assay in H3122 cells transfected with ALK-si or NC-si. We found that lincROR expression was markedly restrained after the knockdown of ALK, indicating that lincROR expression may be associated with ALK ( Figure 2 , P,0.05).
Overexpression of lincrOr rescued a part of stem cell-like properties of H3122 cells which were impaired by alK knockdown
Sphere formation assay, flow cytometry analysis, and qPCR assay were used to explore the effects of ALK knockdown or lincROR overexpression on stem cell-like properties of H3122 cells. Sphere formation assay illustrated that the spheroid rate of H3122 cells transfected with ALK-si and pcDNA-control was lower than that of cells transfected with NC-si and pcDNA-control, but lincROR overexpression resulted in enhanced spheroid rate of H3122 cells transfected with ALK-si ( Figure 3A) . We observed that 6.857% (mean value, MD) CD133 + CD44 + in NC-si + pcDNA-control group, 1.327% (mean value, MD) in ALK-si + pcDNA-control group, and 4.583% (mean value, MD) in ALK-si + pcDNAlincROR group. The results indicated that ALK knockdown reduced the percentage of CD133 +
CD44
+ in H3122 cells, but lincROR overexpression could partly improve the percentage of CD133 + CD44 + in H3122 cells ( Figure 3B ). Results obtained with qPCR showed that Sox2, Nanog, and OCT4 expressions in ALK-si+pcDNA control group were all significantly lower than those in NC-si+pcDNA control group, indicating that ALK knockdown contributed to a decrease of Sox2, Nanog, and OCT4 expressions ( Figure 3C, P,0.05) . Conversely, Sox2, Nanog, and OCT4 expressions in ALKsi+pcDNA lincROR group were evidently higher than those in ALK-si+pcDNA control group, revealing that overexpression of lincROR upregulated the Sox2, Nanog, and OCT4 expressions when they were repressed by ALK knockdown ( Figure 3C, P,0.05) . Taken together, the results revealed that lincROR overexpression could enhance stemness features of EML-ALK + NSCLC cells, which were repressed by ALK knockdown.
lincROR expression was inhibited by increased concentration of crizotinib in h2228 and h3122 cell lines
To determine the correlation of lincROR with crizotinib, we detected lincROR expression at different concentrations of crizotinib in A549, H2228, and H3122 cells, respectively. As displayed in Figure 4A , no obvious impact of crizotinib on lincROR expression was observed in A549 cells (P,0.05). However, remarkable downregulation of lincROR was detected in both H2228 and H3122 cells as a result of increased concentration of crizotinib ( Figure 4B and C, P,0.05). These results implied that crizotinib could influence lincROR expression.
lincrOr overexpression elevated chemoresistance to crizotinib in H3122 and h2228 cells
The effects of lincROR and crizotinib on cell viability of EML4-ALK + NSCLC cells were explored. The results showed that the inhibitory effect of crizotinib on cell viability was increased with its increasing concentrations. The cell viability of H3122 cells was significantly higher in pcDNAlincROR group as compared to pcDNA-control at various concentrations (0.25, 0.5, 1.0, and 5.0 μM) of crizotinib, respectively ( Figure 5A, P,0.05) . This was the case in H2228 cells ( Figure 5B, P,0.05) . It could be observed that lincROR overexpression elevated the chemoresistance to crizotinib in both H3122 and H2228 cells.
Discussion
EML4-ALK fusion has been identified as a causative factor in patients with NSCLC. 29 lincROR, a key reprogramming regulator, has been found in different cancers where it acts as an oncogene. 22, 26, 27 Especially in NSCLC, the oncogenic role and prognostic value of lincROR have been outlined as previously reported. 30 However, little is known about the role 
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Yang et al of lincROR in EML-ALK-induced NSCLC. In this study, we first found elevated expression of lincROR in EML-ALK + tissues in comparison with EML-ALK − tissues. Additionally, we found a favorable prognosis in low-expressed lincROR patients with EML-ALK + NSCLC, in accordance with a previous finding. 30 These results inspired us to speculate that lincROR might govern the tumorigenesis, progression, and prognosis of EML-ALK + NSCLC. 
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Notably, EML-ALK is an activator for a variety of downstream signaling molecules such as STAT3, ERK, and AKT, which play a key role in inducing and maintaining stem-like properties for CSCs. 28 It has been reported that CSCs have the capacity of increasing tumorigenesis and the potential of forming tumor metastasis. Furthermore, EML4-ALK has been discovered as the inducer for a stem-like phonotype in NSCLC cells. 5, 6, 28 Major transcription factors, including OCT4, SOX2, and NANOG, are important for pluripotent stem cell phenotype. 31 Of note, lincROR can be directly modulated by OCT4, SOX2, and NANOG. 32 In addition, lincROR is involved in various cancers by acting as a tumor-promoting factor. It was, therefore, tempting to speculate some correlation between EML-ALK and lincROR in stem cell-like properties of NSCLC. In our work, lincROR exhibited downregulated expression in H3122 cells after transfection with ALK-si. We further discovered that stem cell-like properties of H3122 cells were downregulated after transfection with ALK-si. Interestingly, H3122 cells transfected with ALK-si displayed rescued stem cell-like properties induced by lincROR overexpression. Therefore, it is reasonable to presume that ALK could regulate the stemness features of EML-ALK + NSCLC cells, possibly by modulating lincROR.
Crizotinib serves as the therapeutic drug for patients with EML-ALK + NSCLC by directly targeting ALK and shows the anticancer activity in patients with ALK-positive NSCLC. 33 Nevertheless, the occurrence of crizotinib resistance commonly leads to tumor recurrence and cancer metastasis. 9 Pan et al have demonstrated that lincROR is associated with chemoresistance in NSCLC. 25 To the best of our knowledge, the correlation between lincROR and crizotinib in EML-ALK + NSCLC is less reported. Herein, we detected the expression pattern of lincROR in different concentrations of crizotinib. Our results indicated that lincROR expression was negatively correlated with the concentration of crizotinib. Moreover, we also found that lincROR could elevate cell viability of EML-ALK + NSCLC cells, which was suppressed by crizotinib. These results indicated lincROR may promote acquired resistance to crizotinib in EML-ALK + NSCLC. In summary, this study provides a new insight into the important role of lincROR in the prognosis, stem cell-like properties, as well as acquired crizotinib resistance in EML-ALK + NSCLC. However, this work also has some limitations. The functional role of lincROR in EML-ALK + NSCLC and the concrete mechanism of lincROR in acquired crizotinib resistance were not explored. Further work should be conducted to gain a better understanding about the biological role of lincROR and how lincROR interacts with crizotinib in EML-ALK + NSCLC.
Conclusion
This study reveals a key role of lincROR in the stemness features and the acquired crizotinib resistance associated with EML-ALK + NSCLC, implying that lincROR could be a potential target in the prognosis and treatment of EML-ALK + NSCLC. Further studies should concentrate on elucidating the exact molecular mechanisms of lincROR and crizotinib jointly acting on EML-ALK + NSCLC.
